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Background: The completeness of REarranged during Transfection (RET) testing in patients with 
medullary thyroid carcinoma (MTC) was recently reported as 60%. However, the completeness on 
a population level is unknown. Similarly, it is unknown if the first Danish guidelines from 2002, 
recommending RET testing in all MTC patients, improved completeness in Denmark. We con-
ducted a nationwide retrospective cohort study aiming to evaluate the completeness of RET testing 
in the Danish MTC cohort. Additionally, we aimed to assess the completeness before and after 
publication of the first Danish guidelines and characterize MTC patients who had not been tested.
Methods: The study included 200 patients identified from the nationwide Danish MTC cohort 
1997–2013. To identify RET tested MTC patients before December 31, 2014, the MTC cohort 
was cross-checked with the nationwide Danish RET cohort 1994–2014. To characterize MTC 
patients who had not been RET tested, we reviewed their medical records and compared them 
with MTC patients who had been tested.
Results: Completeness of RET testing in the overall MTC cohort was 87% (95% CI: 0.81–0.91; 
173/200). In the adjusted MTC cohort, after excluding patients diagnosed with hereditary MTC 
by screening, completeness was 83% (95% CI: 0.76–0.88; 131/158). Completeness was 88% 
(95% CI: 0.75–0.95; 42/48) and 81% (95% CI: 0.72–0.88) (89/110) before and after publica-
tion of the first Danish guidelines, respectively. Patients not RET tested had a higher median 
age at diagnosis compared to those RET tested. Median time to death was shorter in those not 
tested relative to those tested.
Conclusion: The completeness of RET testing in MTC patients in Denmark seems to be higher 
than reported in other cohorts. No improvement in completeness was detected after publication 
of the first Danish guidelines. In addition, data indicate that advanced age and low life expec-
tancy at MTC diagnosis may serve as prognostic indicators to identify patients having a higher 
likelihood of missing the compulsory RET test.
Keywords: RET testing, medullary thyroid carcinoma, Denmark
Introduction
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor with an incidence 
of 0.19 per 100,000 per year and a prevalence of 3.8 per 100,000 inhabitants.1 MTC 
is divided into sporadic (75%) and hereditary (25%).1,2 The latter form occurs as part 
of multiple endocrine neoplasia (MEN)2, which is an autosomal-dominant inherited 
cancer syndrome, where virtually all patients develop MTC and variable proportions 
develop pheochromocytoma, primary hyperparathyroidism, cutaneous lichen amy-
loidosis, Hirschsprung’s disease, ganglioneuromatosis of the aerodigestive tract, and 
facial, ophthalmologic, and skeletal abnormalities.3 Conversely, the sporadic form is 
not known to have familial implications or predispositions to other endocrine neopla-
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sia. It is thus important to distinguish hereditary MTC from 
sporadic MTC.
As germline mutations of the REarranged during Trans-
fection (RET) proto-oncogene are present in practically all 
patients with hereditary MTC and absent in patients with 
sporadic MTC, distinction is best made by RET testing on 
peripheral blood.4 Presence of a RET germline mutation 
has serious implications for index cases and their families. 
Hence, index cases will need lifelong follow-up and screen-
ing for MEN2 manifestations other than MTC. Meanwhile, 
all first-degree relatives should be offered genetic counseling 
and genetic testing. If the relatives are positive of the family 
germline mutation, virtually all will require prophylactic 
thyroidectomy with the timing depending on the specific 
mutation. As for the index cases, relatives will also warrant 
lifelong follow-up for development of MEN2 manifestations. 
Thus, for several years, international guidelines have recom-
mended RET testing of all patients with MTC.3,5,6
The first study aiming to determine the completeness of 
RET testing in MTC patients recently reported a complete-
ness of 60% (86/142) in a single center.7 This completeness is 
remarkably discordant with both past and current recommen-
dations.3,5,6 However, it is unknown if such low completeness is 
also the standard when examining a population-based cohort.
In Denmark, RET testing has been available since Sep-
tember 1994.8 Seven years later, in February 2002, the first 
Danish guidelines, recommending RET testing of all patients 
with MTC, were published.9 In the meantime, it is unknown if 
these guidelines have improved completeness of RET testing 
in MTC patients.
Consequently, we conducted the first population-based 
study aiming to evaluate the overall completeness of RET 
testing in a nationwide MTC cohort. Additionally, we aimed 
to assess the completeness before and after publication of 
the Danish guidelines and characterize MTC patients who 
had not been tested.
Methods
Design and setting
This investigation is a nationwide retrospective cohort study 
including all patients with newly diagnosed MTC in Denmark 
between January 1, 1997, and December 31, 2013.
Data sources
The Danish MTC cohort
This cohort formed the basis for the study. It initially com-
prised 476 patients diagnosed with histological (n=474) or 
cytological (n=2) MTC in Denmark between January 1960 
and December 2014 and was constructed through three 
nationwide registries: the Danish Cancer Registry, the Dan-
ish Thyroid Cancer Database, and the Danish Pathology 
Register as described in detail elsewhere.1,10–13,36 The Danish 
Cancer Registry, the Danish Thyroid Cancer Database, and 
the Danish Pathology Register are considered to cover the 
whole country from 1987, 1996, and 1997, respectively. The 
MTC cohort consisted of an uncertain period from 1960 to 
1996, where complete coverage could not be guaranteed, and 
a nationwide period from 1997 to 2014, where coverage of 
the entire country was considered complete. TNM staging in 
the MTC cohort was performed according to the seventh and 
eighth editions of the American Joint Committee on Cancer 
Staging Manual.14,15
The Danish RET cohort
This nationwide cohort was cross-checked with the Danish 
MTC cohort to determine the completeness of RET testing. 
The cohort initially contained all 1,583 patients RET tested 
in Denmark between September 1994 and December 2014. 
However, in the process of this study, we discovered three 
RET tested patients, whose test had initially been missed. 
Accordingly, the Danish RET cohort comprises 1,586 RET 
tested patients from 1994 to 2014. There was virtually no lag 
time between when a test was performed and when it was 
registered in the Danish RET cohort, as tests were registered 
instantly upon requisition. The cohort has been described and 
used on several occasions.8,16
study participants
From the Danish MTC cohort, we extracted all 224 patients 
diagnosed in the nationwide period from January 1, 1997, 
to December 31, 2014. As RET testing post mortem is not 
considered a standard procedure in Denmark, we excluded 
all patients (n=4) diagnosed at autopsy.17 The original end 
date of the MTC cohort is similar to that of the RET cohort 
(December 31, 2014). Thus, to provide at least 1 year to 
detect RET testing in patients diagnosed during the last 
year (2013) of the MTC cohort, we excluded the patients 
(n=20) diagnosed from January 1, 2014, to December 
31, 2014. This formed an overall MTC cohort comprising 
200 patients, who were alive at the time of diagnosis in 
the study period from January 1, 1997, to December 31, 
2013.
Virtually, all patients diagnosed with hereditary MTC 
by screening (asymptomatic) will have undergone predic-
tive RET testing. Including such patients in the calculations 
may cause a false increase in completeness of RET tested 
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MTC patients for the whole study period and for periods 
where large families with hereditary MTC were discovered. 
The latter could potentially bias a comparison of complete-
ness between two periods. We therefore excluded patients 
diagnosed with hereditary MTC by screening (n=42). This 
yielded an adjusted MTC cohort of 158 patients diagnosed 
from January 1, 1997, to December 31, 2013.
Based on the publication date of the first Danish guide-
lines, February 7, 2002, we divided the adjusted MTC cohort 
into an early period comprising 48 patients diagnosed from 
1, 1997, to February 6, 2002, and a late period comprising 
113 patients diagnosed from February 7, 2002, to December 
31, 2013.
For each patient, data were collected from the MTC and 
RET cohort on sex, date, and TNM stage at MTC diagnosis, 
RET test result and date of result, and survival time. The latter 
was calculated as the time from MTC diagnosis until death, 
emigration, or last follow-up (January 1, 2014), whichever 
came first. To explain why some patients had not been RET 
tested, we reviewed the medical records of these patients for 
any remarks of RET or genetic testing.
statistical analyses
Completeness was calculated as the number of RET tested 
MTC patients divided by the total number of MTC patients 
and was given in percentage with 95% CI. Continuous data 
were presented as median and IQR. Categorical data were 
presented as absolute and relative frequencies. Continuous 
and categorical data were tested on univariate analysis with 
the Mann–Whitney–Wilcoxon-rank test and Fischer’s exact 
test as appropriate. In survival data, censoring was taken into 
account by the Kaplan–Meier method. All tests were two-
sided, and P-values <0.05 were considered as significant. All 
analyses were done using Stata® 15.1 (StataCorp LP, College 
Station, TX, USA).
The investigation was approved by the Danish Health 
Authority (3-3013-395/3) and the Danish Data Protection 
Agency (18/17801).
Results
Overall completeness
In the overall MTC cohort, 87% (95% CI: 0.81–0.91; 
173/200) of the patients diagnosed from January 1, 1997, to 
December 31, 2013, had been RET tested. Of the RET tested 
patients, 71% (122/173) had sporadic MTC and 29% (51/173) 
had hereditary MTC. In the latter patients, the following RET 
mutations were detected: C611W (n=3), C611Y (n=31), 
C618F (n=1), C618Y (n=3), C620R (n=4), C634Y+Y791F 
(n=1), L790F (n=1), A883F (n=1) and M918T (n=6). Several 
of these patients have been reported earlier.17–23
In the adjusted MTC cohort, in which patients diagnosed 
with hereditary MTC by screening had been excluded, the 
completeness of RET testing was 83% (95% CI: 0.76–0.88; 
131/158).
Completeness before and after guidelines
In the early period, 88% (95% CI: 0.75–0.95; 42/48) had 
been RET tested, while this was the case for 81% (95% CI: 
0.72–0.88; 89/110) in the late period. Completeness of RET 
testing in the adjusted MTC cohort according to year of MTC 
diagnosis is depicted in Figure 1.
not RET tested
In the adjusted MTC cohort, 17% (27/158) of patients had 
not been RET tested (Table 1). For 20 patients, we found 
no reason for the lack of RET testing, as no medical record 
was available for two patients and no remark of testing was 
noted in the medical record of 18 patients. In three patients, 
testing was not performed due to advanced age. RET testing 
was planned in two patients but never performed for reasons 
unknown. Two patients had been tested for MEN1 instead 
of MEN2.
Table 2 lists characteristics for those RET tested and those 
not RET tested. At the time of MTC diagnosis, those not 
RET tested had a higher median age and higher proportion 
of distant metastases compared to those RET tested. At the 
last follow-up, the median time to death was shorter in those 
not RET tested compared to those RET tested.
Discussion
Although MEN2 is rare, recognition of the syndrome by 
RET testing is crucial, as early thyroidectomy before MTC 
has spread beyond the thyroid often confers the best chance 
for cure.13,24,37
In this nationwide study, we report a completeness of RET 
testing in >80% of patients diagnosed with MTC in Denmark 
from 1997 to 2013. We found no change in completeness when 
comparing completeness in periods before and after publica-
tion of the first Danish guidelines on the subject. Additionally, it 
seems that MTC patients with an advanced age and a short life 
expectancy have a higher likelihood of not being RET tested.
limitations
The completeness estimate in this study is limited by the pos-
sibility that some patients from the MTC cohort (1997–2013) 
may have been tested after the end date of the RET cohort 
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Figure 1 Completeness of RET testing in patients with MTC in Denmark from 1997 to 2013.
Abbreviations: RET, REarranged during Transfection; MTC, medullary thyroid carcinoma.
Table 1 Characteristics of 27 patients diagnosed with MTC in Denmark 1997–2013 but not RET tested before the end date of the 
Danish RET cohort, December 31, 2014
Patient 
No.
Sex At diagnosis At last follow-up Medical record review
Age, years TNMa Status Survivalb
1 F 76 T1bn0M0 Dead 1.2 no remark of RET testing
2 F 48 T1bn0M0 alive 14.9 no remark of RET testing
3 F 77 T4an0M0 alive 13.9 no remark of RET testing
4 M 82 T3n1bM0 Dead 1.2 no remark of RET testing
5 M 80 T4an1bM1 Dead 0.3 no remark of RET testing
6 M 44 T3n0M0 Dead 0.6 no remark of RET testing
7 F 75 T2n1bM1 Dead 1.3 no remark of RET testing
8 F 75 TXn0M1 Dead 2.6 no remark of RET testing
9 M 60 T4an1aM1 Dead 0.5 no remark of RET testing
10 F 45 T2n1aM0 alive 6.8 no remark of RET testing
11 F 75 T4an1bM1 Dead 0.1 no remark of RET testing
12 F 71 T3n1bM1 Dead 0.2 no remark of RET testing
13 M 40 T4an1bM1 Dead 1.0 no remark of RET testing
14 M 62 T1bn1bM0 alive 2.6 no remark of RET testing
15 M 66 T2n0M0 alive 2.2 no remark of RET testing
16 M 75 T2n1bM0 alive 1.8 no remark of RET testing
17 F 82 T1an0M0 Dead 2.9 no remark of RET testing
18 F 71 T2n1bM0 Dead 0.7 no remark of RET testing
19 F 74 T1an1bM0 Dead 1.9 no medical record available
20 F 73 T4an1bM0 Dead 0.05 no medical record available
21 F 70 T1bn0M0 alive 12.5 RET testing not performed due to advanced age
22 M 84 T4an1aM0 Dead 1.1 RET testing not performed due to advanced age
23 F 76 T2n1bM0 Dead 6.4 RET testing not performed due to advanced age and childlessness
24 F 54 T2n0M0 alive 12.7 RET testing planned but never performed
25 M 69 T4an1bM0 Dead 2.2 RET testing planned but never performed
26 F 62 T3n0M0 alive 6.1 RET testing ordered but MEN1 testing performed
27 F 45 T1an0M0 alive 6.2 RET testing possibly performed but could not be documented
Notes: astaging was based on the american Joint Committee on Cancer’s seventh and eighth editions.14,15 bSurvival was defined as the time from diagnosis of MTC until death, 
emigration, or last follow-up (December 31, 2014), whichever came first.
Abbreviations: F, female; RET, REarranged during Transfection; M, male.
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(1994–2014). This could result in a marginally higher com-
pleteness than reported. In our experience, however, most 
patients are tested within the first year of MTC diagnosis.
Our description of reasons for the lack of RET testing in 
MTC patients was limited by the retrospective collection of 
data from medical records. Medical records were available for 
93% (25/27) of patients who had not been tested. However, 
18 medical records contained no remark of RET testing, 
preventing us from drawing further conclusions in these 
patients. A reasonable thought, however, may be that RET 
testing in these cases was simply forgotten or not considered.
Overall completeness
In the present study, we found a RET testing completeness 
of more than 80%. Recently, the first study aiming to deter-
mine the completeness of RET testing in MTC patients was 
published. The study was based on the Southern California 
Kaiser Permanente health care network and reported a com-
pleteness of 60% (86/142).7 Often such differences between 
Danish and US cohorts may be explained by a different 
access to health care systems. However, all patients from 
the Californian study obtained medical insurance from the 
Kaiser Permanente health care network and all patients in 
Denmark are provided with free public health care. Thus, 
there seems to be equal access to health care in the two study 
cohorts. Another potential explanation could be differences 
in the setup of RET testing in the two cohorts. After the 
diagnosis of MTC in Denmark, patients are offered RET 
testing at the surgical department or referred directly to 
another department that offers testing. The absent details 
of testing setup in the Kaiser Permanente study, however, 
prevent direct comparison. On the other hand, the Kaiser 
study described an outreach project, in which 32 MTC 
patients, who had not been RET tested, were scheduled 
for genetic counseling. However, only 25% (8/32) showed 
interest for their appointment and accepted RET testing. 
Although having no direct Danish comparison, one could 
speculate that the reluctance toward RET testing may have 
been higher in the Kaiser Permanente study cohort com-
pared to the Danish cohort.
Recent institutional studies, with inclusion periods 
roughly similar to ours, have reported a RET testing com-
pleteness of 39%–66% in MTC patients undergoing thyroid 
surgery.25–27 In addition, in this context, the completeness in 
Denmark seems fairly high. However, relative to the recom-
mendation of a completeness of 100%, the Danish complete-
ness is not sufficient.
Completeness before and after guidelines
We saw no change in completeness of RET tested patients 
with MTC diagnosed before and after publication of the first 
Danish guidelines. Thus, judged solely from this, the Dan-
ish guidelines did not improve outcome, as is often a goal 
for clinical guidelines.28 On the other hand, as we also did 
not find a decrease in the completeness, the guidelines may 
have helped to maintain a roughly unchanged completeness 
in the late period compared to that in the early period. One 
may also argue that the completeness in the early period was 
unexpectedly high (88%), potentially due to a commendable 
awareness prompted by the discovery in 1993 and 1994 
that mutations in the RET proto-oncogene cause hereditary 
MTC.29–33 To the best of our knowledge, no other study has 
investigated the temporal changes in RET testing complete-
ness of MTC patients with respect to national guidelines. 
Table 2 Characteristics of 158 patients evaluated for RET testing 
following diagnosis of MTC in Denmark from 1997 to 2013
Characteristics RET tested 
(n=131)
Not RET 
tested (n=27)
At diagnosis
sex, n (%)
F 84 (64) 17 (63)
M 47 (36) 10 (37)
age, median (iQr), years 55.5 (43.0–65.5) 71.5 (60.0–76.0)
T category, n (%)
T0 1 (1) 0
T1 39 (30) 7 (26)
T2 44 (34) 7 (26)
T3 18 (14) 4 (15)
T4 28 (21) 8 (30)
Tx 1 (1) 1 (4)
n category, n (%)
n0 57 (44) 11 (41)
n1 74 (56) 16 (59)
M category, n (%)
M0 119 (91) 20 (74)
M1 12 (9) 7 (26)
TnM stagea, n (%)
i 21 (16) 5 (19)
ii 31 (24) 4 (15)
iii 10 (8) 1 (4)
iV 68 (52) 17 (63)
Unknown 1 (1) 0
At follow-up
survival status
alive 89 (68) 10 (37)
Dead 42 (32) 17 (63)
Time to death, medianb 
(95% Ci) (years)
14.7 (11.3–na) 2.2 (1.0–na)
Notes: Owing to rounding up, not all sums of percentages fit. astaging was based on 
the american Joint Committee on Cancer’s seventh and eighth editions.14,15 bTaking 
censoring into account by the Kaplan–Meier method. no upper limit for the 95% 
Ci due to too few events.
Abbreviations: F, female; M, male; M, metastasis; MTC, medullary thyroid 
carcinoma; n, node; na, not available; RET, REarranged during Transfection; T, 
tumor.
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However, research groups from the US have conducted 
population-based studies exploring surgical practice in regard 
to MTC guidelines.34,35 Thus, a study of 2,033 MTC patients 
included from the Surveillance, Epidemiology, and End 
Results Program database 1973–2006 examined adherence 
to the 2009 American Thyroid Association guidelines and 
found that 41% of patients diagnosed with MTC from 1988 
to 2006 received surgical treatment that was out of line with 
the guidelines.6,34 Additionally, a study of 609 MTC patients 
identified from the California Cancer Registry 1999–2012 
reported that central neck dissection was underused despite 
recommendation of this procedure in both the 2009 and 2015 
American Thyroid Association guidelines.35 Thus, there are 
indications that other parts of the clinical practice for MTC 
are also discordant with guidelines.
not RET tested
To identify MTC patients having a higher likelihood of 
missing the recommended RET test, we performed a 
medical record review in patients who had not been RET 
tested. Although the circumstances of not RET testing were 
described in a limited number of medical records, there 
seems to be a fraction of patients (3/27) who were not RET 
tested due to advanced age. This is consistent with the 
higher age at diagnosis noted in those not tested relative to 
those tested. Although remaining speculative, this may also 
apply for some of the patients who were not tested and had a 
medical record with no remark of RET testing. Additionally, 
39% (7/18) of patients with no remark of RET testing in the 
medical record lived less than 1 year from MTC diagnosis to 
death. Thus, some patients may simply not live long enough 
to undergo RET testing (as they often need to be referred to 
and convened by the RET testing department). This is sup-
ported by the lower median time from diagnosis to death 
found when comparing those not tested to those tested. In 
addition, we found a higher proportion of distant metastases 
among those not tested compared to those tested. The differ-
ence, however, disappeared after Bonferroni correction in a 
logistic regression model that also incorporated sex, age, T 
category, and N category as predictor variables. Altogether, 
this could indicate that a low life expectancy and an advanced 
age at MTC diagnosis may serve as prognostic indicators for 
identification of MTC patients having a higher likelihood of 
missing the compulsory RET test. The differences among 
the tested and untested patients with regard to median age 
at diagnosis and median time to death are substantial in a 
clinical context, where they may be used as markers to find 
patients needing special attention to secure that RET testing 
is performed. This may improve the completeness of RET 
testing. Another way to improve completeness could be to 
perform RET testing immediately when the patient attending 
the surgical outpatient clinic is informed about the diagnosis 
of MTC. Among the Danish thyroid cancer centers, this setup 
is used in one center, while the remaining three centers use a 
two-tier setup, in which patients after diagnosis are referred 
to another department, where testing is then performed.
Conclusion
The completeness of RET testing in MTC patients in Den-
mark seems to be higher than reported in other cohorts. No 
improvement in completeness was detected after publication 
of the first Danish guidelines recommending RET testing in 
all MTC patients. In addition, our data indicate that advanced 
age and low life expectancy at MTC diagnosis may serve 
as prognostic indicators to identify patients having a higher 
likelihood of missing the compulsory RET test.
Acknowledgments
This work was supported by the University of Southern 
Denmark, the Region of Southern Denmark, the Odense 
University Hospital, the Copenhagen University Hospital, 
the Danish Cancer Society, the Danish Cancer Research 
Foundation, and the A.P. Moller Foundation. 
Disclosure
The research salary of Ulla Feldt-Rasmussen is sponsored by an 
unrestricted research grant from the Novo Nordic Foundation. 
The authors report no other conflicts of interest in this work.
References
 1. Mathiesen JS, Kroustrup JP, Vestergaard P, et al. Incidence and 
prevalence of sporadic and hereditary MTC in Denmark 1960-2014: a 
nationwide study. Endocr Connect. 2018;7(6):829–839.
 2. Raue F, Kotzerke J, Reinwein D, et al. Prognostic factors in medullary 
thyroid carcinoma: evaluation of 741 patients from the German Medul-
lary Thyroid Carcinoma Register. Clin Investig. 1993;71(1):7–12.
 3. Wells SA, Asa SL, Dralle H, et al. Revised American Thyroid Associa-
tion guidelines for the management of medullary thyroid carcinoma. 
Thyroid. 2015;25(6):567–610.
 4. Fink M, Weinhüsel A, Niederle B, Haas OA. Distinction between spo-
radic and hereditary medullary thyroid carcinoma (MTC) by mutation 
analysis of the RET proto-oncogene. “Study Group Multiple Endocrine 
Neoplasia Austria (SMENA)”. Int J Cancer. 1996;69(4):312–316.
 5. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and ther-
apy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86(12): 
5658–5671.
 6. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, 
et al. Medullary thyroid cancer: management guidelines of the American 
Thyroid Association. Thyroid. 2009;19(6):565–612.
 7. Parkhurst E, Calonico E, Abboy S. Utilization of genetic testing for RET 
mutations in patients with medullary thyroid carcinoma: a single-center 
experience. J Genet Couns. 2018;27(6):1411–1416.
 
C
lin
ic
al
 E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
87
.5
3.
13
1.
88
 o
n 
28
-J
an
-2
01
9
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2019:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Clinical Epidemiology
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/clinical-epidemiology-journal
Clinical Epidemiology is an international, peer-reviewed, open access, 
online journal focusing on disease and drug epidemiology, identifica-
tion of risk factors and screening procedures to develop optimal pre-
ventative initiatives and programs. Specific topics include: diagnosis, 
prognosis, treatment, screening, prevention, risk factor modification, 
systematic reviews, risk and safety of medical interventions, epidemiol-
ogy and biostatistical methods, and evaluation of guidelines, translational 
medicine, health policies and economic evaluations. The manuscript 
management system is completely online and includes a very quick 
and fair peer-review system, which is all easy to use.
Dovepress
99
Completeness of RET testing in MTC patients in Denmark 1997–2013
 8. Mathiesen JS, Kroustrup JP, Vestergaard P, et al. Distribution of RET 
mutations in multiple endocrine Neoplasia 2 in Denmark 1994-2014: 
a nationwide study. Thyroid. 2017;27(2):215–223.
 9. Andersen PH, Kroustrup JP, Feldt-Rasmussen UF. Multipel endokrin 
neoplasi: Screening, diagnostik, behandling og efterkontrol: Oversigt 
og vejledende retningslinjer udarbejdet af Dansk MEN-arbejdsgruppe 
under Dansk Endokrinologisk Selskab. Lægeforeningens forlag. 2002.
 10. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 
2011;39(7 Suppl):42–45.
 11. Londero SC, Mathiesen JS, Krogdahl A, et al. Completeness and validity 
in a national clinical thyroid cancer database: DATHYRCA. Cancer 
Epidemiol. 2014;38(5):633–637.
 12. Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Peder-
sen L. Existing data sources for clinical epidemiology: the Danish National 
Pathology Registry and Data Bank. Clin Epidemiol. 2010;2:51–56.
 13. Mathiesen JS, Kroustrup JP, Vestergaard P, et al. Incidence and preva-
lence of multiple endocrine neoplasia 2B in Denmark: a nationwide 
study. Endocr Relat Cancer. 2017;24(7):L39–L42.
 14. Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual. 7th 
ed. New York, NY: Springer; 2010.
 15. Amin MB, Edge SB, Greene FL. AJCC Cancer Staging Manual. 8th 
ed. New York, NY: Springer; 2017.
 16. Mathiesen JS, Kroustrup JP, Vestergaard P, et al. Founder Effect of the 
RETC611Y Mutation in Multiple Endocrine Neoplasia 2A in Denmark: 
a Nationwide Study. Thyroid. 2017;27(12):1505–1510.
 17. Godballe C, Jørgensen G, Gerdes AM, Krogdahl AS, Tybjaerg-Hansen 
A, Nielsen FC. Medullary thyroid cancer: RET testing of an archival 
material. Eur Arch Otorhinolaryngol. 2010;267(4):613–617.
 18. Mathiesen JS, Dossing H, Bender L. Medullary thyroid carcinoma in 
a 10-month-old child with multiple endocrine neoplasia 2B. Ugeskr 
Laeger. 2014;176(5a), pii.
 19. Emmertsen K. Screening for hereditary medullary cancer in Denmark. 
Henry Ford Hosp Med J. 1984;32(4):238–243.
 20. Mathiesen JS, Habra MA, Bassett JHD, et al. Risk profile of the RET 
A883F germline mutation: an international collaborative study. J Clin 
Endocrinol Metab. 2017;102(6):2069–2074.
 21. Mathiesen JS, Stochholm K, Poulsen PL, Vestergaard EM, Christiansen 
P, Vestergaard P. Aggressive medullary thyroid carcinoma in a ten-year-
old patient with multiple endocrine neoplasia 2B due to the A883F 
mutation. Thyroid. 2015;25(1):139–140.
 22. Vestergaard P, Kroustrup JP, Rønne H, Eng C, Laurberg P. Neuromas in 
multiple endocrine neoplasia type 2A with a RET codon 611 mutation. 
J Endocr Genet. 1999;1(1):33–37.
 23. Hansen HS, Torring H, Godballe C, Jäger AC, Nielsen FC. Is thyroid-
ectomy necessary in RET mutations carriers of the familial medullary 
thyroid carcinoma syndrome? Cancer. 2000;89(4):863–867.
 24. Mathiesen JS, Kroustrup JP, Vestergaard P, et al. Incidence and preva-
lence of multiple endocrine neoplasia 2A in Denmark 1901-2014: a 
nationwide study. Clin Epidemiol. 2018;10:1479–1487.
 25. Kwon H, Kim WG, Sung TY, et al. Changing trends in the clinicopatho-
logical features and clinical outcomes of medullary thyroid carcinoma. 
J Surg Oncol. 2016;113(2):152–158.
 26. Kwon H, Kim WG, Jeon MJ, et al. Dynamic risk stratification for 
medullary thyroid cancer according to the response to initial therapy. 
Endocrine. 2016;53(1):174–181.
 27. Cho YY, Jang HW, Jang JY, et al. Clinical outcomes of patients with 
hypercalcitoninemia after initial treatment for medullary thyroid cancer 
and postoperative serum calcitonin cutoffs for predicting structural 
recurrence. Head Neck. 2016;38(10):1501–1508.
 28. Weisz G, Cambrosio A, Keating P, Knaapen L, Schlich T, Tournay VJ. 
The emergence of clinical practice guidelines. Milbank Q. 2007;85(4): 
691–727.
 29. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-
oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 
1993;2(7):851–856.
 30. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the 
RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 
1993;363(6428):458–460.
 31. Carlson KM, Dou S, Chi D, et al. Single missense mutation in the tyro-
sine kinase catalytic domain of the RET protooncogene is associated 
with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA. 
1994;91(4):1579–1583.
 32. Eng C, Smith DP, Mulligan LM, et al. Point mutation within the tyro-
sine kinase domain of the RET proto-oncogene in multiple endocrine 
neoplasia type 2B and related sporadic tumours. Hum Mol Genet. 
1994;3(2):237–241.
 33. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET 
proto-oncogene associated with multiple endocrine neoplasia type 2B 
and sporadic medullary thyroid carcinoma. Nature. 1994;367(6461): 
375–376.
 34. Panigrahi B, Roman SA, Sosa JA. Medullary thyroid cancer: are prac-
tice patterns in the United States discordant from American Thyroid 
Association guidelines? Ann Surg Oncol. 2010;17(6):1490–1498.
 35. Kuo EJ, Sho S, Li N, Zanocco KA, Yeh MW, Livhits MJ. Risk factors 
associated with reoperation and disease-specific mortality in patients 
with medullary thyroid carcinoma. JAMA Surg. 2018;153(1):52–59.
 36. Mathiesen JS, Kroustrup JP, Vestergaard P, et al. Replication of newly 
proposed TNM staging system for medullary thyroid carcinoma: a 
nationwide study. Endocr Connect. Epub 2018 Dec 1.
 37. Mathiesen JS, Kroustrup JP, Vestergaard P, et al. Survival and long-
term biochemical cure in medullary thyroid carcinoma in Denmark 
1997–2014: A nationwide study. Thyroid. In press 2019.
 
C
lin
ic
al
 E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
87
.5
3.
13
1.
88
 o
n 
28
-J
an
-2
01
9
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
